Biosimilar monoclonal antibodies: The next frontier. a summary report from a symposium held at EAHP 2012

European Journal of Hospital Pharmacy

Volumn 19, Issue 3, 2012, Pages 315-317

  Dingermann, Theodor ^a   Windisch, Jörg ^b   Cornes, Paul ^c  

^a GOETHE UNIVERSITY   (Germany)

^b Sandoz Pharma Ltd   (Switzerland)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; RITUXIMAB;

ARTICLE; BIOEQUIVALENCE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG QUALITY; DRUG SAFETY; HOSPITAL PHARMACY; HUMAN; MEDICAL SOCIETY; NEOPLASM; SYMPOSIUM;

EID: 84871353435     PISSN: 20479956     EISSN: 20479964     Source Type: Journal    
DOI: 10.1136/ejhpharm-2012-000139     Document Type: Article

References (5)

1. Chernew ME, Hirth RA, Cutler DM. Increased spending on health care: longterm implications for the nation. Health Aff (Millwood) 2009;28:1253-1255.
2. Grabowski H, Cockburn I, Long G. The market for follow-on biologics: how will it evolve? Health Aff (Millwood) 2006;25:1291-1301.
3. The competitive role of biosimilars in the German SHI market for pharmaceuticals (IGES Institute GmbH, data on file at Sandoz, January 2009).
4. Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract. 2012;18:171-179.
5. Press release: World cancer day 2012, World cancer day 2012: EAHP and ESOP issue joint call for pharmacist development to advance cancer care, 080212, at: http://www.eahp.eu/News/Our-News/Press-release-WORLD-CANCER-DAY-2012 (accessed March 2012).